{"id":740706,"date":"2023-03-16T08:34:18","date_gmt":"2023-03-16T12:34:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/"},"modified":"2023-03-16T08:34:18","modified_gmt":"2023-03-16T12:34:18","slug":"cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/","title":{"rendered":"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MINNEAPOLIS, March  16, 2023  (GLOBE NEWSWIRE) &#8212; CVRx, Inc. (\u201cCVRx\u201d), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim\u2122, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, reiterated plans to discuss the preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure Therapeutics (THT) conference on Tuesday, March 21, 2023 at 10:58 am Eastern Time in Boston. These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC).<\/p>\n<p>Additionally, CVRx will sponsor a symposium, \u201cBaroreflex Activation Therapy in HFrEF: New Insights from the BeAT-HF Study\u201d, at the THT 2023 conference starting at 12:30 pm ET. Dr. Zile\u2019s slides and the slides presented at the symposium will be filed on a Form 8-K concurrent with Dr. Zile\u2019s presentation.<\/p>\n<p>In conjunction, the Company will host an investor conference call at 4:30 pm Eastern Time the same day to discuss the results. A live webcast of the investor conference call will be available online at the investor relations page of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4nt4zOa2C7hRGdZFCUR4W0o_5pgk9FqCiJZgHygIsQaaru2GTrw4KvlftlyCqAKHXh3VGtPc5t7CUit7gMY12g==\" rel=\"nofollow noopener\" target=\"_blank\">ir.cvrx.com<\/a>. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.<\/p>\n<p>\n        <strong>About CVRx, Inc.<\/strong>\n      <\/p>\n<p>CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim\u2122 is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body\u2019s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KmalN5u5gQH5caR9k_c4jhJtJeOpn-cDM9Q0fv3IJbnaKIoXqjoiyO26RLTBhLwmWxnSnVBWaBxSWQGp4zirnw==\" rel=\"nofollow noopener\" target=\"_blank\">www.cvrx.com<\/a>.<\/p>\n<p>Investor Contact:<\/p>\n<p>Mark Klausner or Mike Vallie<br \/>ICR Westwicke<br \/>443-213-0501<br \/>ir@cvrx.com<\/p>\n<p>Media Contact:<\/p>\n<p>Laura O\u2019Neill<br \/>Finn Partners <br \/>212-867-1762<br \/>laura.oneill@finnpartners.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzMwNGEyM2UtNzgzMi00ZThhLWEzNzQtMWQwYTdhZTkxYzJlLTEyMjA4OTI=\/tiny\/CVRx-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) &#8212; CVRx, Inc. (\u201cCVRx\u201d), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim\u2122, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, reiterated plans to discuss the preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure Therapeutics (THT) conference on Tuesday, March 21, 2023 at 10:58 am Eastern Time in Boston. These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC). Additionally, CVRx will sponsor a symposium, \u201cBaroreflex Activation Therapy in HFrEF: New Insights from the BeAT-HF Study\u201d, at the THT 2023 conference starting at 12:30 pm ET. Dr. Zile\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740706","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) &#8212; CVRx, Inc. (\u201cCVRx\u201d), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim\u2122, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, reiterated plans to discuss the preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure Therapeutics (THT) conference on Tuesday, March 21, 2023 at 10:58 am Eastern Time in Boston. These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC). Additionally, CVRx will sponsor a symposium, \u201cBaroreflex Activation Therapy in HFrEF: New Insights from the BeAT-HF Study\u201d, at the THT 2023 conference starting at 12:30 pm ET. Dr. Zile\u2019s &hellip; Continue reading &quot;CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T12:34:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call\",\"datePublished\":\"2023-03-16T12:34:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/\"},\"wordCount\":411,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/\",\"name\":\"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=\",\"datePublished\":\"2023-03-16T12:34:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/","og_locale":"en_US","og_type":"article","og_title":"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call - Market Newsdesk","og_description":"MINNEAPOLIS, March 16, 2023 (GLOBE NEWSWIRE) &#8212; CVRx, Inc. (\u201cCVRx\u201d), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim\u2122, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, reiterated plans to discuss the preliminary results of the post-market phase of the BeAT-HF trial at the second annual Technology and Heart Failure Therapeutics (THT) conference on Tuesday, March 21, 2023 at 10:58 am Eastern Time in Boston. These results will be presented by Dr. Michael Zile, Professor of Cardiology at the Medical University of South Carolina (MUSC). Additionally, CVRx will sponsor a symposium, \u201cBaroreflex Activation Therapy in HFrEF: New Insights from the BeAT-HF Study\u201d, at the THT 2023 conference starting at 12:30 pm ET. Dr. Zile\u2019s &hellip; Continue reading \"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-16T12:34:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call","datePublished":"2023-03-16T12:34:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/"},"wordCount":411,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/","name":"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=","datePublished":"2023-03-16T12:34:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTQxNSM1NDY1MDc4IzIyMDkzMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-reiterates-plans-to-discuss-the-preliminary-results-from-the-post-market-phase-of-the-beat-hf-trial-at-tht-2023-and-schedules-a-conference-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CVRx Reiterates Plans to Discuss the Preliminary Results from the Post-Market Phase of the BeAT-HF Trial at THT 2023 and Schedules a Conference Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740706"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740706\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}